Invesco’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-23,698
| Closed | -$5.23M | – | 3753 |
|
|
2025
Q4 | $5.23M | Sell |
23,698
-133,474
| -85% | -$21.6M | ﹤0.01% | 2229 |
|
|
2025
Q3 | $15.1M | Buy |
157,172
+31,746
| +25% | +$2.03M | ﹤0.01% | 1592 |
|
|
2025
Q2 | $6.11M | Buy |
+125,426
| New | +$3.01M | ﹤0.01% | 2074 |
|
|
2023
Q4 | – | Sell |
-2,111
| Closed | -$39.8K | – | 3836 |
|
|
2023
Q3 | $39.8K | Buy |
2,111
+860
| +69% | +$16.9K | ﹤0.01% | 3816 |
|
|
2023
Q2 | $28.3K | Buy |
+1,251
| New | +$29.4K | ﹤0.01% | 3851 |
|
|
2021
Q2 | – | Sell |
-1,431
| Closed | -$76K | – | 3973 |
|
|
2021
Q1 | $76K | Buy |
1,431
+53
| +4% | +$2.62K | ﹤0.01% | 3794 |
|
|
2020
Q4 | $55K | Buy |
+1,378
| New | +$68.5K | ﹤0.01% | 3735 |
|
|
2019
Q1 | – | Sell |
-7,569
| Closed | -$356K | – | 3719 |
|
|
2018
Q4 | $356K | Sell |
7,569
-21
| -0.3% | -$1.5K | ﹤0.01% | 3399 |
|
|
2018
Q3 | $668K | Sell |
7,590
-3,303
| -30% | -$291K | ﹤0.01% | 3313 |
|
|
2018
Q2 | $1.13M | Buy |
+10,893
| New | +$1.03M | ﹤0.01% | 3070 |
|
|
2015
Q3 | – | Sell |
-18
| Closed | -$5K | – | 3816 |
|
|
2015
Q2 | $5K | Buy |
+18
| New | +$5.54K | ﹤0.01% | 4191 |
|
Invesco's CDTX Position: Q1 2026 in Review
Invesco sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 23,698 shares — an estimated $5.23M sold.
Invesco first reported a position in CDTX in Q2 2015 and held it in 11 quarters. The position peaked at $15.1M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Invesco reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Invesco sold 23,698 Cidara Therapeutics shares in Q1 2026, an estimated $5.23M.
- Invesco first reported a position in Cidara Therapeutics in Q2 2015 and held it in 11 quarters.
- Invesco's Cidara Therapeutics position peaked at $15.1M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.